by Megan Hollasch
Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal … Read more
A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more
by Jessica Nye, PhD
A systematic review found that fertility and parenthood were important and affected quality of life for young patients with gynecologic cancers; however, counseling and referral to fertility services is suboptimal. These findings were published in The … Read more
Reviewed by Emily Henderson, B.Sc.
JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that … Read more
by The ASCO Post Staff
Frequent aspirin use may be linked with lower ovarian cancer risk in individuals with multiple risk factors, according to a new study published by Hurwitz et al in the Journal of Clinical Oncology.
“Ovarian … Read more
by Emily Henderson, B.Sc.
Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that cancer turns the body’s defenses against itself. However, new research from Nagoya University published in Matrix Biology suggests … Read more
by Vicki Moore, PhD
A recent study evaluated the effects programs aimed at addressing food insecurity have on treatment outcomes for patients with cancer. Each intervention seemed beneficial, with a voucher-plus-pantry program appearing to be the most effective. The study’s … Read more
NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.
For … Read more
by Coco Davis/ Fred Hutchinson Cancer Research Center
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy among women in the United States (US). Although the incidence rate is higher among White women, Black women have the lower survival … Read more
by Jennifer Byrne
Women with recurrent ovarian cancer experience an average of 14 disease or treatment-related symptoms at any given time over the course of their disease.
“It’s a huge symptom burden,” Heidi Donovan, PhD, RN, professor of health and … Read more
by University of Chicago Medical Center
Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our
… Read moreBiomedical engineer Daniel Heller leads the Cancer Nanomedicine Laboratory at MSK.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a sensor that can be trained to sniff for cancer, with the help of artificial intelligence.
Although the training … Read more
by the ASCO Post Staff
Today, 1 year after its founding, Break Through Cancer announced $50 million in grants to support several cutting-edge research projects using a novel “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, … Read more
Scientists from the University of California (UC), San Diego, and their collaborators have demonstrated how key proteins act together to suppress antitumor activity in high-grade serous ovarian carcinoma (HGSOC) in a mouse model, revealing a new combinatorial strategy to treat … Read more
by Charles Bankhead
— Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk
The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis … Read more
by Jennifer Southall
Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.
The findings, presented during the Society of Gynecologic Oncology 2022 Annual … Read more
Approach can help radiologists in a busy clinical practice assess lesions more quickly
The appearance of ovarian lesions on ultrasound is an effective predictor of cancer risk that can help women avoid unnecessary surgery, according to a new study published … Read more
by Emily Henderson, B.Sc.
High-grade serous carcinoma is the most aggressive form of ovarian cancer and accounts for the majority of advanced-stage cases. The poor outcomes associated with the disease underscore the need for more effective treatments. A research team … Read more
by Jade Boyd
Rice immunotherapy treatment could begin human clinical trials this year
HOUSTON – (March 2, 2022) – Rice University bioengineers have shown they can eradicate advanced-stage ovarian and colorectal cancer in mice in as little as six days
NEW YORK – A team led by researchers at the University of Helsinki has uncovered stress-related tumor and microenvironment gene expression features that appear to coincide with chemotherapy resistance and shorter progression-free survival in individuals with high-grade serous ovarian cancer.… Read more
